These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20457723)

  • 1. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
    Yoo C; Kim JE; Lee JL; Ahn JH; Lee DH; Lee JS; Na S; Kim CS; Hong JH; Hong B; Song C; Ahn H
    Jpn J Clin Oncol; 2010 Oct; 40(10):980-5. PubMed ID: 20457723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
    Miyake H; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jun; 38(6):3593-3599. PubMed ID: 29848715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
    Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
    Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
    Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
    Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
    Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
    Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
    Edesa WA; Abdelmalek RR
    Asian Pac J Cancer Prev; 2015; 16(5):1971-6. PubMed ID: 25773796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 11. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
    Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
    Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    van der Veldt AA; Boven E; Helgason HH; van Wouwe M; Berkhof J; de Gast G; Mallo H; Tillier CN; van den Eertwegh AJ; Haanen JB
    Br J Cancer; 2008 Jul; 99(2):259-65. PubMed ID: 18594533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.
    Liu X; Fiocco M; Swen JJ; Guchelaar HJ
    Acta Oncol; 2017 Apr; 56(4):582-589. PubMed ID: 27924664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
    Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
    Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
    Shi HZ; Tian J; Li CL
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
    J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
    Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
    Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.